Daré Bioscience, Inc. (DARE) News
Filter DARE News Items
DARE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DARE News Highlights
- For DARE, its 30 day story count is now at 6.
- Over the past 25 days, the trend for DARE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about DARE are BIO, MA and MS.
Latest DARE News From Around the Web
Below are the latest news stories about DARE BIOSCIENCE INC that investors may wish to consider to help them evaluate DARE as an investment opportunity.
Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal DisorderSildenafil Cream-treated patients showed meaningful improvement in the co-primary endpoint assessment that evaluated change from baseline in the Arousal-Sensation Domain of the Sexual Function Questionnaire Sildenafil Cream-treated patients also showed improvements in the secondary endpoint and pre-specified exploratory endpoints that evaluated sexual satisfaction, arousal lubrication, and achievement and pleasure of orgasm Data support continued development of Sildenafil Cream and selection of |
Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT ConferenceSAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two conferences during the week of June 5th: BIO International Convention, being held June 5-8, 2023 at the Boston Convention and Exhibition Center in Boston, MA. Ms. Johnson will provide a corporate overview on Tuesday, June 6th at 12:00 p.m. EDT.Longwood Healthcare Leaders Sp |
Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual MedicineThe Concept Elicitation Study Informed the Selection of the Primary, Secondary, and Exploratory Endpoints Included in the Phase 2b RESPOND Clinical Study Evaluating the Efficacy and Safety of Sildenafil Cream, 3.6% in Premenopausal Patients with Female Sexual Arousal Disorder Topline Data from the Exploratory Phase 2b RESPOND Study are Anticipated 2Q-2023 SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the pu |
Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2023 Earnings Call TranscriptDaré Bioscience, Inc. (NASDAQ:DARE) Q1 2023 Earnings Call Transcript May 11, 2023 Daré Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.1. Operator: Welcome to the conference call hosted by Daré Bioscience to review the Company’s Financial Results for the Quarter Ended March 31, 2023, and to provide a General Business Update. […] |
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue EstimatesDare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 10% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company UpdateConference Call and Webcast Today at 4:30 p.m. ET 2023 Anticipated Milestones: Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder Phase 2b Clinical Study Topline DataXACIATO™ First Commercial SaleOvaprene Pivotal Contraceptive Efficacy Study InitiationDARE-PDM1 Phase 1 Clinical Study Topline DataActivities to support IND Submission and Clinical Study Initiation for DARE-VVA1 (Phase 2) and DARE-HRT1 (Phase 3) SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), |
Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 11, 2023, to review its financial results for the quarter ended March 31, 2023 and to provide a Company update. To access the conference call via phone, dial (800) 715-9871 (U.S.) or (646) 307-1963 (international). The conference ID number for the call is 7046999. Th |
Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%Phase 1 Thermography Study Quantitative Data Expected to Complement Patient Reported Outcome Data Collected in the Exploratory Phase 2b RESPOND At-Home Study Topline Data for the Exploratory Phase 2b RESPOND Study Anticipated in 2Q-2023 SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced initiation of sc |
David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, GermanySAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will be presenting in the Keynote Forum of the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany. Dr. Friend’s talk is scheduled from 9:00 – 9:25 AM CEST on April 24th and is titled: Safety and Pharmacokinetic Assessment of Ovaprene®, A Once-Monthly No |
Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone TherapyDaré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Climacteric, the official journal of the International Menopause Society, published safety and a |